The combination of leuprolide and enzalutamide demonstrates a substantial survival benefit for men with locally advanced or recurrent high-risk prostate cancer, according to the multinational EMBARK phase III trial. Researchers report a 40.3 percent drop in overall mortality compared with leuprolide alone, with eight-year survival improving from 69.5 to 78.9 percent.
Case Spotlight: Patil’s Journey Through High-Risk Disease
Suresh Patil, a 65-year-old from Mumbai, presented with elevated PSA levels (16 ng/mL) and a high Gleason score, indicating aggressive cancer. Initial treatment included radical prostatectomy with pelvic lymph node removal and targeted radiotherapy. Despite early biochemical control, PSA rose again within a year, signaling biochemical recurrence. His clinical team proceeded with a calibrated EMBARK-based regimen: leuprolide injections and enzalutamide tablets. PSA declined from 2.8 ng/mL to undetectable levels within six months, allowing cessation of therapy after 37 weeks. He remains in remission with quarterly PSA monitoring.
How the Drug Duo Works in Prostate Cancer
The strategy attacks cancer from two angles: leuprolide suppresses testosterone production, while enzalutamide blocks residual testosterone signaling in cancer cells. This dual blockade is designed to slow tumor growth, potentially shrink lesions, and delay metastasis. Experts emphasize that early detection through screening remains crucial for timely intervention in aggressive disease.
EMBARK Trial: Design and Key Findings
In EMBARK, nearly 1,000 men with high-risk biochemical recurrence across 17 countries were randomized to three arms: enzalutamide plus leuprolide, leuprolide alone, or enzalutamide alone, in a 1:1:1 ratio. The combined therapy significantly improved survival versus leuprolide alone, with a reported 40.3 percent reduction in deaths. Eight-year survival was 78.9 percent for the combination group compared with 69.5 percent for leuprolide monotherapy. While most patients maintained stable PSA during treatment, a minority exhibited aggressive cancer biology requiring continued surveillance.
Clinical Implications and Screening Messages
Screening remains a critical tool for identifying prostate cancer at a stage amenable to curative or life-extending interventions. The American Cancer Society recommends discussing PSA testing and digital rectal exams with a healthcare provider, particularly for those with risk factors such as family history or known genetic mutations. In India and other regions facing rising incidence, widening access to effective regimens like the leuprolide-enzalutamide combination could influence survival outcomes for high-risk patients.
Two Expert Perspectives
Dr. Amit Joshi, Professor of Medical Oncology at ACTREC, notes that the dual-therapy approach aligns with modern oncologic strategies to target hormonal drivers of prostate cancer. He underscores the importance of indication-driven screening to catch aggressive disease early. Dr. Kamlesh Bokil adds that while the combination shows promise, patient selection remains crucial, as responses can vary based on tumor biology and prior treatments.
Practical Considerations for Clinicians
Patient selection: identify those at high risk for recurrence post-surgery/radiation, using PSA dynamics and Gleason scores.
Monitoring: implement regular PSA testing and imaging as indicated to detect early signs of progression or biochemical recurrence.
Side effects and management: anticipate potential adverse effects of hormonal therapy and androgen receptor blockade, and provide supportive care as needed.
Related topics
OHIP Should Cover PSA Test Costs to Improve Prostate Cancer Detection
Testicular Cancer: Breaking Silence and Saving Lives through Early Detection
